To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Accessibility StatementSkip Navigation forward-looking statements should not be relied upon as representing Leap's views as of any date subsequent to the date hereof. CONTACT: Douglas E. OnsiPresident & Chief Executive OfficerLeap Therapeutics, Inc.617-714-0360[email protected] CAMBRIDGE, Mass., Sept. 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present the final clinical res ...

Accessibility StatementSkip Navigation – Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over Placebo in the Overall Study Population and Consistent Effects Across Subtypes – – CALLIPER Data Showed Positive and Consistent Signals for Slowing Disability Progression Across Disability Endpoints, Patient Populations and Subgroups Without Evidence of Focal Inflammation, ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Amgen Inc. (NASDAQ: AMGN ) has not been a great performer in the last two years. The stoc ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Amgen (NASDAQ: AMGN ) has not been a great performer in the last two years. The stock is ...

Committed to solid profitable growth Investor Introduction Q3 2025 Presentation Titel Forward looking and intended use statements Crucial to advancing science Improving healthcare for all Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, d ...

Investors once speculated that Pfizer might consider acquiring Viking.Weight loss drugs have represented an enormous growth area for biotech and pharma companies over the past couple of years. Pharma giants Eli Lilly and Novo Nordisk dominate the market with their drugs and have brought in billions of dollars in revenue as demand skyrocketed. In fact, last year demand was so high -- surpassing supply at certain points -- that these drugs were on the U.S. Food and Drug Administration's drug shortage list.Sin ...

系统性红斑狼疮 （SLE） 是一种慢性自身免疫疾病，其特征是产生靶向多个器官系统的自身抗体，从而导致多样的临床表现以及较高的发病率和死亡率。尽管包 括皮质类固醇、免疫抑制剂和生物制剂在内的疗法有所进步，但许多 难治性系统性红斑狼疮 （rSLE） 患者对常规治疗仍反应不佳，这凸显了开发新型治疗策略 的必要性。 目前，美国 FDA 以批准了多款 CAR-T 细胞疗法 用于治疗血液系统癌症，这些疗法要么靶向 CD19，要么靶向 BCMA。自 2021 年以来，已有多项研究报道了 靶向 CD19 的CAR-T 细胞疗法 在系统性红斑狼疮等自身免疫疾病中的有效性和安全性，然而将其与 靶向 BCMA 的 CAR-T 细胞疗法 相结合的研究，仍十分有 限。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 2025 年 9 月 24 日，浙江大学医学院附属第一医院 黄河 教授、 胡永仙 教授、 林进 主任 医师、 浙江大学医学院附属邵逸夫医院 鲁林荣 教授、复旦大学/上海 雅科生物 张鸿声 博士作为共同通讯作者，在 Nature Medicine 期刊发表了题为： Co-infusion of CD19-targeting and ...

MeiraGTx Holdings plc (NASDAQ: MGTX ) is a genetic medicines biotech with a late-stage pipeline and capabilities for end-to-end GMP manufacturing. Its main drug candidates are AAV-AIPL1 for congenital blindness, which is working toward exceptional-circumstances filings and has a plannedMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens ...

PepGen Inc. PEPG shares surged 119.55% to $5.84 during after-hours trading on Wednesday following the clinical-stage company’s announcement of an underwritten public offering. Check out the current price of PEPG stock here. Public Offering Details Drive Market ResponseThe Cambridge, Massachusetts-based biotech has announced the launch of an underwritten public offering of common stock and pre-funded warrants. Leerink Partners and Stifel SF are acting as joint book-running managers for the offering, with the ...